Analyze Diet

Efficacy of trivalent inactivated encephalomyelitis virus vaccine in horses.

Abstract: Twenty-nine horses were vaccinated with a trivalent (Venezuelan, eastern, and western) inactivated equine encephalomyelitis virus vaccine. The vaccine purchased for this study was the only one licensed and commercially available in May, 1975. Plaque-neutralizing and hemagglutinin-inhibiting antibodies in response to each of the 3 equine encephalomyelitis viruses were determined after vaccination. Horses had rising levels of plaque-neutralizing and hemagglutinin-inhibiting antibodies shortly after injection with the 1st and 2nd doses of the vaccine (given 3 weeks apart) and were refractory to challenge of immunity with virulent homologous virus at 3, 8, and 12 months after vaccination. After 12 months, 8 horses were revaccinated; maximum antigenic stimulation was achieved with the 1st dose of the 2nd series of vaccinations.
Publication Date: 1978-04-01 PubMed ID: 646197
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The researchers studied the effectiveness of a licensed trivalent equine encephalomyelitis virus vaccine in 29 horses, which induced immunity for at least a year after administered in two doses, three weeks apart. The vaccine efficacy was monitored through attesting the levels of specific antibodies, and the horses showed successful immune response to virulent virus exposure even after 12 months of vaccination.

Study Overview

  • Researchers conducted a study on 29 horses to test the efficacy of a trivalent (targeting Venezuelan, eastern, and western strains) equine encephalomyelitis virus vaccine.
  • The vaccine used was the only licensed and commercially available product in May 1975.
  • The response to vaccination was evaluated by measuring the production of plaque-neutralizing and hemagglutinin-inhibiting antibodies targeting the three types of encephalomyelitis virus.

Vaccine Response and Efficacy

  • The horses developed higher levels of these antibodies after the first and second dose of the vaccine, which were administered three weeks apart.
  • The study found that the horses were immune to the challenge of immunity with virulent homologous virus at 3, 8, and 12 months after being vaccinated, indicating the vaccine’s efficacy in providing prolonged immunity.

Revaccination and Antigenic Stimulation

  • Twelve months after the initial vaccination, the researchers revaccinated eight of the horses.
  • The maximum antigenic stimulation, or the maximum immune response, was seen after the first dose of this second round of vaccinations.
  • This suggests that a secondary series of vaccinations may further boost immune response, though more research would be necessary to confirm this finding and its implications.

Conclusion

  • The study confirms the efficacy of the trivalent equine encephalomyelitis virus vaccine in horses, with a robust and lasting immune response observed for at least a year after vaccination.
  • The vaccine prompted an increase in plaque-neutralizing and hemagglutinin-inhibiting antibodies, demonstrating the body’s immune response to the vaccine.
  • The study could have significant implications for disease prevention and control strategies among equine populations.

Cite This Article

APA
Barber TL, Walton TE, Lewis KJ. (1978). Efficacy of trivalent inactivated encephalomyelitis virus vaccine in horses. Am J Vet Res, 39(4), 621-625.

Publication

ISSN: 0002-9645
NlmUniqueID: 0375011
Country: United States
Language: English
Volume: 39
Issue: 4
Pages: 621-625

Researcher Affiliations

Barber, T L
    Walton, T E
      Lewis, K J

        MeSH Terms

        • Animals
        • Antibodies, Viral / analysis
        • Encephalitis Virus, Eastern Equine / immunology
        • Encephalitis Virus, Venezuelan Equine / immunology
        • Encephalitis Virus, Western Equine / immunology
        • Encephalitis Viruses / immunology
        • Encephalomyelitis, Equine / prevention & control
        • Encephalomyelitis, Equine / veterinary
        • Encephalomyelitis, Venezuelan Equine / prevention & control
        • Encephalomyelitis, Venezuelan Equine / veterinary
        • Female
        • Horse Diseases / prevention & control
        • Horses
        • Male
        • Viral Vaccines / administration & dosage
        • Viral Vaccines / standards

        Citations

        This article has been cited 10 times.
        1. Skidmore AM, Bradfute SB. The life cycle of the alphaviruses: From an antiviral perspective.. Antiviral Res 2023 Jan;209:105476.
        2. Desanti-Consoli H, Bouillon J, Chapuis RJJ. Equids' Core Vaccines Guidelines in North America: Considerations and Prospective.. Vaccines (Basel) 2022 Mar 4;10(3).
          doi: 10.3390/vaccines10030398pubmed: 35335029google scholar: lookup
        3. More S, Bøtner A, Butterworth A, Calistri P, Depner K, Edwards S, Garin-Bastuji B, Good M, Gortázar Schmidt C, Michel V, Miranda MA, Nielsen SS, Raj M, Sihvonen L, Spoolder H, Stegeman JA, Thulke HH, Velarde A, Willeberg P, Winckler C, Baldinelli F, Broglia A, Dhollander S, Beltrán-Beck B, Kohnle L, Morgado J, Bicout D. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): equine encephalomyelitis (Eastern and Western).. EFSA J 2017 Jul;15(7):e04946.
          doi: 10.2903/j.efsa.2017.4946pubmed: 32625598google scholar: lookup
        4. Amaya M, Keck F, Lindquist M, Voss K, Scavone L, Kehn-Hall K, Roberts B, Bailey C, Schmaljohn C, Narayanan A. The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.. PLoS One 2015;10(4):e0124792.
          doi: 10.1371/journal.pone.0124792pubmed: 25927990google scholar: lookup
        5. Pauvolid-Corrêa A, Juliano RS, Campos Z, Velez J, Nogueira RM, Komar N. Neutralising antibodies for Mayaro virus in Pantanal, Brazil.. Mem Inst Oswaldo Cruz 2015 Feb;110(1):125-33.
          doi: 10.1590/0074-02760140383pubmed: 25742272google scholar: lookup
        6. Go YY, Balasuriya UB, Lee CK. Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses.. Clin Exp Vaccine Res 2014 Jan;3(1):58-77.
          doi: 10.7774/cevr.2014.3.1.58pubmed: 24427764google scholar: lookup
        7. Pandya J, Gorchakov R, Wang E, Leal G, Weaver SC. A vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation.. Vaccine 2012 Feb 8;30(7):1276-82.
          doi: 10.1016/j.vaccine.2011.12.121pubmed: 22222869google scholar: lookup
        8. Atasheva S, Wang E, Adams AP, Plante KS, Ni S, Taylor K, Miller ME, Frolov I, Weaver SC. Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus.. Vaccine 2009 Jul 9;27(32):4309-19.
          doi: 10.1016/j.vaccine.2009.05.011pubmed: 19446595google scholar: lookup
        9. Magnarelli LA, Bushmich SL, Anderson JF, Ledizet M, Koski RA. Serum antibodies to West Nile virus in naturally exposed and vaccinated horses.. J Med Microbiol 2008 Sep;57(Pt 9):1087-1093.
          doi: 10.1099/jmm.0.47849-0pubmed: 18719177google scholar: lookup
        10. Elvinger F, Baldwin CA, Liggett AD, Tang KN, Dove CR. Protection of pigs by vaccination of pregnant sows against eastern equine encephalomyelitis virus.. Vet Microbiol 1996 Aug;51(3-4):229-39.
          doi: 10.1016/0378-1135(96)00037-5pubmed: 8870186google scholar: lookup